Cellular Dynamics signs on with AstraZeneca for drug discovery
Cellular Dynamics has struck a deal with AstraZeneca, agreeing to provide stem cells for AZ's drug-discovery efforts.
Analysts: 2013 could be big for CROs
Last year, growth in the CRO world was mostly flat, but analysts at Sterne, Agee & Leach say contract researchers could be posied for growth in 2013.
India group wants change in clinical trial regs for children
India's clinical trial regulations (or lack thereof) have long been the subject of international debate, and now the country's National Commission for Protection of Child Rights is looking to enact standardized rules for trials on children, saying many are subjected to studies without their parents being made aware.
WuXi, PRA plan to launch joint venture in China
WuXi PharmaTech and PRA are joining forces to launch an independent CRO in China, combining their capacities in the country to create a jointly owned venture for Phase I-IV clinical trial services.
Chinese CRO ShangPharma looks to go private
After months of rumors, ShangPharma is pulling the trigger on a deal that will take it private, creating a parent company that unites private equity firms and some of the CRO's leadership.
GoBalto rakes in $12M for cloud-based clinical development
San Francisco's goBalto has pulled in $12 million in Series B financing to advance its cloud-based clinical development platform, which allows sponsors and CROs to monitor and collaborate on study results.
Parexel drops $72M on regulatory info outfit
Parexel International is looking to bolster its regulatory consulting business, spending $72 million on Liquent, maker of software solutions for submissions and registrations.
Patheon closes $255M Banner deal
With T's crossed and I's dotted, CDMO Patheon has closed its $255 million acquisition of Banner Pharmacaps, maker of gelatin-based dosage forms.
Texas Tech gets into the CRO game
We've seen countless headlines about CROs teaming up with universities on drug discovery and clinical trials, but here's a novel arrangement: Texas Tech is looking to launch a CRO of its own through a local business accelerator.
Warnex closes bioanalytics sale, exits CRO biz
Canada's Warnex has sold off its final business unit, closing a deal that ships its bioanalytical services division to Biotrial Research for about $6.1 million, and now it has to decide whether to liquidate or regroup.
Charles River projects a modest 2013, slides on the Street
Investors were none too pleased with Charles River Laboratories' outlook for 2013, as the CRO fell as much as 8% after projecting growth below analyst estimates.
Catalent inks biosimilar deal with Japanese CMO
Catalent has signed a deal to provide biosimilar cell lines to Japan's UMN Pharma, a development and manufacturing agreement designed to jump-start the CMO's presence on the Asian market.
Quintiles recruiting for AstraZeneca's novel depression drug
AstraZeneca is reaching out to Quintiles as it gathers data on AZD6765, part of a newfangled class of depression drugs that promises to beat what's on the market.
Parexel opens Chinese customer care office for eClinical clients
Perceptive Informatics, Parexel International's eClinical unit, has opened a customer care office in Shanghai to assist its digital trial management clients there and help drive adoption of its products in the country.
TFS snags Italy's Dimensione Ricerca, targeting late-stage trials
Swedish CRO TFS International is buying up Dimensione Ricerca, an Italian contract researcher, aiming to expand its European capabilities for cross-continent, late-stage clinical trials.
Recipharm bets on analytical development with expansion
Swedish CDMO Recipharm is banking on a growing demand for analytical drug development services, planning to reconstruct its Solna, Sweden, facility to house its data-based offerings.
Covance notches GLP nod from Chinese regulators
Covance picked up a Good Laboratory Practice Certificate for its Shanghai early development facility, a regulatory milestone the CRO says gives it a leg up on global competitors.
Alimera taps Quintiles to commercialize Iluvien
Alimera Sciences is facing an uphill battle getting its chronic diabetic macular edema drug on shelves in Europe, and now the company has recruited Quintiles to manage the European launch of Iluvien.
AMRI re-ups with GE Healthcare, its largest supply partner
Amid budget-slashing and restructuring, AMRI has some good news to report: The CRO has re-signed with GE Healthcare to supply materials for diagnostic imaging, locking down its biggest commercial supply client through 2016.
NextPharma sells off U.S. CMO operation
CMO NextPharma has sold its U.S. manufacturing operation, Bioserv, to private equity player KESA Partners for an undisclosed sum, planning to focus on its core European operation.
